FDA cleared the EXG PulseLinQ Cables (EXGPL) from Cb Innovations, LLC on Oct 30, 2026 under K262816, a traditional 510(k). The device falls under product code DSA, Cable, Transducer And Electrode, Patient, (Including Connector), regulated at 21 CFR 870.2900 as a Class 2 device. The review panel was Cardiovascular.

FDA logged the submission as received on Aug 7, 2026. The decision came 84 days later, inside the 90 FDA-day goal for a 510(k).

This is the only decision on file for Cb Innovations, LLC in the last 12 months of the tracker.